FDA clears Elekta's iViewDose dosimetry software

Elekta, a Stockholm-based clinical solutions company, announced today that its iViewDose software has received 501(k) clearance from the FDA.

According to the company, the new dosimetry software provides an efficient solution for the detection of radiotherapy errors, potentially detecting more errors than other alternative pretreatment verification methods.

The software, a joint project from Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), also received financing from Netherlands granting body Technology Foundation STW.

“iViewDose can detect several errors that can’t be detected with pre-treatment checks, such as phantoms in combination with an ionization chamber or diode arrays,” Igor Olaciregui-Ruiz, product developer at NKI-AVL, said in a press release. “These error sources include variations in patient anatomy or patient position and the effect of immobilization devices on dose calculation and delivery among other types of errors.”

 

 

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.